Wide Ranks

IQV

IQVIA Holdings, Inc.

201.43

Top Statistics
Market Cap 36 B Forward PE 16.59 Revenue Growth 4.30 %
Current Ratio 0.81 Trailing PE 26.47 Earnings Growth -4.90 %
Profit Margins 9.17 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 17.26 Enterprise / Revenue 3.19 Price To Sales Trailing12 Months 2.39
Profitability
Profit Margins 9.17 % Operating Margins 14.84 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 9.43 Total Debt 13 B
Total Debt To Equity 200.26 Current Ratio 0.81 Book Value Per Share 38.37
All Measures
Short Ratio 191.00 % Message Board Id finmb_137473239 Shares Short Prior Month 2 M
Return On Equity 0.2200 City Durham Uuid a91f775a-c6d1-3b3d-953f-a72e3bb2c3c2
Previous Close 201.23 First Trade Date Epoch Utc 1 B Book Value 38.37
Beta 1.51 Total Debt 13 B Volume 822624
Price To Book 5.25 Fifty Two Week Low 187.62 Total Cash Per Share 9.43
Total Revenue 15 B Shares Short Previous Month Date 1 B Target Median Price 255.00
Max Age 86400 Recommendation Mean 1.60 Sand P52 Week Change 0.3133
Operating Margins 14.84 % Target Mean Price 252.18 Net Income To Common 1 B
Ask 210.00 Short Percent Of Float 0.0210 Implied Shares Outstanding 183 M
Last Fiscal Year End 1 B Trailing Peg Ratio 104.50 % Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 84.11 Held Percent Insiders 0.0092 Ebitda Margins 18.46 %
Trailing PE 26.47 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 201.23 Target Low Price 195.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 220.36 Open 202.06 Free Cashflow 1 B
State NC Dividend Yield 0.00 % Return On Assets 0.0511
Time Zone Short Name EST Trailing Eps 7.61 Day Low 200.82
Address1 2400 Ellis Road Shares Outstanding 181 M Price Hint 2
Target High Price 290.00 Website https://www.iqvia.com 52 Week Change -0.0592
Average Volume 1 M Earnings Quarterly Growth -5.90 % Forward Eps 12.07
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 71.00 %
Is_sp_500 True Regular Market Day High 204.30 Profit Margins 9.17 %
Debt To Equity 200.26 Fifty Two Week High 261.73 Day High 204.30
Shares Short 3 M Regular Market Open 202.06 Industry Key diagnostics-research
Bid 189.91 Earnings Growth -4.90 % Enterprise To Revenue 3.19
Revenue Growth 4.30 % Shares Percent Shares Out 0.0184 Operating Cashflow 2 B
Currency USD Time Zone Full Name America/New_York Market Cap 36 B
Is_nasdaq_100 False Zip 27703 Quote Type EQUITY
Industry Diagnostics & Research Long Name IQVIA Holdings Inc. Regular Market Day Low 200.82
Held Percent Institutions 0.9430 Current Price 201.43 Enterprise To Ebitda 17.26
Financial Currency USD Current Ratio 0.81 Gross Margins 35.17 %
Industry Disp Diagnostics & Research Number Of Analyst Opinions 23 Country United States
Float Shares 176 M Two Hundred Day Average 231.44 Enterprise Value 48 B
Price To Sales Trailing12 Months 2.39 Forward PE 16.59 Regular Market Volume 822624
Ebitda 2 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.

The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.

The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.

It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.

The company has a collaboration with argenx SE.

The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.

The company is headquartered in Durham, North Carolina.